MaxCyte Inc. operates as a commercial-stage provider of cell-engineering platforms focused on accelerating the discovery, development, and manufacturing of next-generation cell and gene therapies. Operating through a unique business model that licenses its proprietary electroporation technology to numerous global biopharmaceutical partners, the company captures milestone and commercial-sale revenues across a vast pipeline of clinical candidates spanning oncology, rare genetic disorders, and autoimmune diseases.